Mutant p53 drives invasion by promoting integrin recycling
- PMID: 20064378
- DOI: 10.1016/j.cell.2009.11.026
Mutant p53 drives invasion by promoting integrin recycling
Abstract
p53 is a tumor suppressor protein whose function is frequently lost in cancers through missense mutations within the Tp53 gene. This results in the expression of point-mutated p53 proteins that have both lost wild-type tumor suppressor activity and show gain of functions that contribute to transformation and metastasis. Here, we show that mutant p53 expression can promote invasion, loss of directionality of migration, and metastatic behavior. These activities of p53 reflect enhanced integrin and epidermal growth factor receptor (EGFR) trafficking, which depends on Rab-coupling protein (RCP) and results in constitutive activation of EGFR/integrin signaling. We provide evidence that mutant p53 promotes cell invasion via the inhibition of TAp63, and simultaneous loss of p53 and TAp63 recapitulates the phenotype of mutant p53 in cells. These findings open the possibility that blocking alpha5/beta1-integrin and/or the EGF receptor will have therapeutic benefit in mutant p53-expressing cancers.
Copyright 2009 Elsevier Inc. All rights reserved.
Similar articles
-
Integrins and mutant p53 on the road to metastasis.Cell. 2009 Dec 24;139(7):1220-2. doi: 10.1016/j.cell.2009.12.016. Cell. 2009. PMID: 20064366
-
Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments.J Cell Biol. 2008 Oct 6;183(1):143-55. doi: 10.1083/jcb.200804140. J Cell Biol. 2008. PMID: 18838556 Free PMC article.
-
Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.Mol Cell Biol. 2007 Dec;27(23):8228-42. doi: 10.1128/MCB.00374-07. Epub 2007 Sep 17. Mol Cell Biol. 2007. PMID: 17875924 Free PMC article.
-
P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.Crit Rev Oncol Hematol. 2013 Nov;88(2):284-92. doi: 10.1016/j.critrevonc.2013.05.003. Epub 2013 Jun 5. Crit Rev Oncol Hematol. 2013. PMID: 23755891 Review.
-
The role of mutant p53 in human cancer.J Pathol. 2011 Jan;223(2):116-26. doi: 10.1002/path.2784. Epub 2010 Oct 25. J Pathol. 2011. PMID: 21125670 Review.
Cited by
-
Vps34 Inhibits Hepatocellular Carcinoma Invasion by Regulating Endosome-Lysosome Trafficking via Rab7-RILP and Rab11.Cancer Res Treat. 2022 Jan;54(1):182-198. doi: 10.4143/crt.2020.578. Epub 2021 Mar 26. Cancer Res Treat. 2022. PMID: 33781048 Free PMC article.
-
Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer.Front Genet. 2022 Sep 2;13:930826. doi: 10.3389/fgene.2022.930826. eCollection 2022. Front Genet. 2022. PMID: 36118863 Free PMC article.
-
ΔNp63α regulates Erk signaling via MKP3 to inhibit cancer metastasis.Oncogene. 2014 Jan 9;33(2):212-24. doi: 10.1038/onc.2012.564. Epub 2012 Dec 17. Oncogene. 2014. PMID: 23246965 Free PMC article.
-
p63 regulates glutaminase 2 expression.Cell Cycle. 2013 May 1;12(9):1395-405. doi: 10.4161/cc.24478. Epub 2013 Apr 10. Cell Cycle. 2013. PMID: 23574722 Free PMC article.
-
Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.PLoS One. 2012;7(1):e30339. doi: 10.1371/journal.pone.0030339. Epub 2012 Jan 23. PLoS One. 2012. PMID: 22291938 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
